IngredientsMing Dang Shen is derived from Changium smyrnioides, a species of flowering plant in the family Apiaceae, belonging to the monotypic genus Changium. The pharmaceutical name for the drug derived from this plant is Changii Radix (also written as Changii Smyrnioidis Radix). The plant's recognized common names include ming dang shen in English transliteration, ming dang shen in Chinese, and is written 明党参 or 明黨參 in Chinese characters. A recognized botanical synonym is Conopodium smyrnioides (H. Wolff) M. Hiroe.
The plant is a herbaceous perennial endemic to Eastern China, distributed in the eastern and central regions of the Yangtze River basin, and mainly found in the northwest region of Zhejiang Province, the southwest region of Jiangsu Province, and the southeast region of Anhui Province. The plant has a spindle-shaped or long-cordiform root, measuring 5–20 cm in length, with a brownish-yellow or pale yellow surface and a white interior.
Ming Dang Shen is frequently and consequentially confused with a different herb. Ming Dang Shen (明党参, Changium smyrnioides), despite its similar common name, is from a completely different plant family (Apiaceae) with different properties from the far more widely known "Dang Shen" (Codonopsis pilosula, family Campanulaceae). Ming Dang Shen should not be conflated with Dang Shen (Codonopsis root), as the two herbs belong to distinct families and have distinct phytochemical profiles and traditional indications. A researcher or practitioner encountering the name "Dang Shen" in classical or modern literature will almost always be reading about the Codonopsis root unless the modifier "Ming" is explicitly included. In the context of adulteration, Changium smyrnioides Wolff (Mingdangshen) appears in the scientific literature as one of the known adulterants for other Apiaceae herbs such as Glehnia littoralis (Beishashen).
The content of water-soluble components in Changii Radix was stipulated to exceed the legal limit of 20% according to the Chinese Pharmacopoeia (2015 edition), which formally recognizes the root as a regulated drug material. Changium smyrnioides Wolff (Apiaceae) is an endangered medicinal plant with numerous pharmacological uses.
Both biological and anthropological factors have contributed to the recent decline of this species, and it is now classified as an endangered species in the Chinese Plant Red Book (Status: Vulnerable species). Changium smyrnioides, an endangered species endemic to China, has a limited distribution range; overharvesting and anthropogenic disturbances have contributed to a steady decline in both its population and range, resulting in habitat fragmentation and loss. Owing to its medicinal importance, demand for Changii Radix has increased steadily in recent years, further stressing wild populations.
The dry roots of C. smyrnioides, commonly referred to as Changii Radix, are the part used as a valuable material in traditional Chinese medicine. In daily life, the root is often sliced and brewed as tea, and is known for being rich in amino acids. It is also widely used to brew medicated liquor and health tea together with other herbs. In contemporary commerce, the root is available as whole dried pieces or as powder for decoction.
Changium smyrnioides Wolff is a monotypic species of the genus Changium Wolff which is only found in eastern China; it has been used as a traditional medicine for ages to treat cough, vomiting, nausea, megrim (migraine-like headache), and carbuncle.
It is important to note that the better-documented historical record of the name "Dang Shen" in classical texts refers to Codonopsis root, not to Ming Dang Shen specifically. Prior to the Ming Dynasty, there was no recorded mention of Codonopsis Radix in historic herbal classics, and the name "Dang Shen" was only formally codified in the Qing Dynasty. For Ming Dang Shen (Changium smyrnioides), its identity as a distinct medicinal material was recognized primarily in regional Chinese practice in the eastern provinces, particularly Zhejiang, Jiangsu, and Anhui.
In the framework of TCM, Ming Dang Shen is classified as a herb with particular actions on specific organ systems. It is traditionally used for its therapeutic properties in clearing the lungs, resolving phlegm, calming the liver, harmonizing the stomach, detoxifying the body, and treating conditions such as cough, wheezing, dizziness, vomiting, red eyes, and leukorrhea caused by phlegm and heat. Its nature is classified as cool, its taste as sweet and slightly bitter, and it is associated with the Lung and Liver organ systems. The TCM actions attributed to Ming Dang Shen include clearing the lungs, transforming phlegm, calming the liver, harmonizing the stomach, and expelling toxins.
It is also widely used to brew medicated liquor and health tea with other herbs in order to moisten the lungs and nourish blood and yin. Historically, it has been used to support the digestive system, particularly for symptoms such as poor appetite, abdominal distention, and weakness associated with chronic digestive complaints; in TCM, Ming Dang Shen is often categorized as a Qi tonic, believed to strengthen the spleen and stomach, which are central to digestion in the traditional framework.
Based on distribution records, C. smyrnioides's primary habitats are concentrated in Zhejiang and Jiangsu provinces, and its traditional medical use has therefore been most deeply rooted in those eastern Chinese regions. Its use in medicated liquors — a regional East Chinese folk practice — reflects a tradition of combining several tonic herbs in an alcohol extraction to enhance bioavailability of active compounds and to support what TCM classifies as Lung-Yin and Blood nourishment.
Active components of Changii Radix include polysaccharides, mannitol, and choline, among others. Phytochemical investigations have revealed that phenylpropanoids, volatile oils, fatty acids, phytosterols, and other bioactive compounds are contained in C. smyrnioides.
A peer-reviewed phytochemical isolation study published in a Chinese-language pharmacological journal identified the following compounds from the root: ten compounds were isolated and identified as lignoceric acid, beta-sitosterol, stigmasterol, 5-hydroxy-8-methoxypsoralen, glycerylmonopalmitate, L-pyroglutamic acid, succinic acid, vanillic acid-4-O-beta-D-glucopyranoside, vanillic acid, and daucosterol. Several of these — including the furanocoumarin 5-hydroxy-8-methoxypsoralen — were identified from the plant for the first time in that study.
Current research on C. smyrnioides predominantly focuses on the pharmacological components derived from its roots, including the extraction and analysis of root chemical constituents, such as the investigation into the distribution patterns of furanocoumarins.
Polysaccharides of Changii Radix can promote immune activity, stress resistance, and intestinal motility, and offer potential application value against cancer and infectious diseases. In cultivation studies examining how light intensity affects bioactive compound accumulation, the highest polysaccharide content measured was 10.80%, achieved under 44.84% sunlight conditions.
Mannitol can be used to treat diuresis, dehydration, antitussive symptoms, expectorant antiasthmatic symptoms, and antioxidant symptoms, and can have a significant effect on many diseases. Mannitol is a well-characterized sugar alcohol present in many plants; it is considered one of the key water-soluble biomarker compounds regulated by the Chinese Pharmacopoeia for quality control of Changii Radix. In the same cultivation study, the highest mannitol content measured was 1.35%, recorded under 31.39% sunlight.
Choline can prevent the deposition of fat into the liver and can regulate liver and gallbladder functioning. Choline, a water-soluble essential nutrient, is present at significant concentrations in the root. In the cultivation study, the highest choline content measured was 405.58 μg/g, recorded under 31.39% sunlight.
The root bark of C. smyrnioides contains furanocoumarins — a class of compounds distributed across many Apiaceae plants. An in vitro study investigated the antitumor activity of five furanocoumarins from the root bark of Changium smyrnioides. The furanocoumarin 5-hydroxy-8-methoxypsoralen was identified among isolated constituents; furanocoumarins as a chemical class are known to have phototoxic and photosensitizing properties.
Phytochemical profiling has confirmed the presence of phenylpropanoids, volatile oils, fatty acids, and phytosterols in the plant. Isolated phytosterols include beta-sitosterol, stigmasterol, and daucosterol — compounds common to many medicinal plants and associated in the broader literature with various biological activities.
Crude extracts and monomeric compounds isolated from C. smyrnioides have significant effects on the respiratory, immune, and vascular systems and exhibit favourable activities such as antitussive, eliminating phlegm, anti-asthmatic, immunoregulatory, antioxidant, anti-tumor, anti-fatigue, anti-hypoxia, and anti-atherosclerotic effects. The immunoregulatory effects are attributed substantially to the polysaccharide fraction. The pharmacological basis for immune function modulation by Changii Radix polysaccharides has been a focus of research dating back to the early 1990s in Chinese pharmacological literature.
Research work done in the recent past has shown that Changii Radix has pharmacological uses including as a cough suppressant and immune function regulator. The antitussive activity has historically been one of the herb's primary documented pharmacological functions in both classical and modern Chinese medicine contexts, and is consistent with the high mannitol content, which can be used to treat antitussive symptoms and expectorant antiasthmatic symptoms.
Additional pharmacological activities documented in the literature for Changii Radix include antifatigue, antioxidant, antilipemic, anticoagulant, and antimutation effects, as well as promotion of small intestine motility.
Changium smyrnioides is among the Apiaceae plants that have demonstrated antitumor activity in research settings. In vitro research has specifically evaluated furanocoumarins isolated from the root bark for cytotoxic effects on cancer cell lines. This work remains preliminary and preclinical.
Crude extracts and monomeric compounds isolated from C. smyrnioides have significant effects on the vascular system and exhibit anti-atherosclerotic effects. Anticoagulant properties have been reported in studies examining the effect of processed Radix Changii on clotting time and platelet aggregation, though this body of evidence is based on Chinese-language primary studies and has not been independently replicated in controlled international trials.
The scientific evidence base for Ming Dang Shen (Changium smyrnioides) is substantially different in character and volume from evidence available for more widely studied herbs. Further studies on the bioactive compounds and mechanisms of C. smyrnioides are necessary, and additional clinical and toxicological studies are warranted to evaluate its safety. As of the most recent available review in the peer-reviewed literature (published in the Journal of Natural Medicines, 2018), no controlled human clinical trials of Changii Radix as a standalone intervention had been published. Virtually all the pharmacological evidence currently available is derived from in vitro cell studies, preclinical animal experiments, or observational ethnopharmacological reports. This is an important limitation to state clearly.
Evidence level: Preclinical (in vitro and animal); no human clinical trials identified.
Studies on crude extracts and monomeric compounds isolated from C. smyrnioides have identified antitussive, phlegm-eliminating, and anti-asthmatic activities as among the most documented pharmacological effects on the respiratory system. The antitussive activity, which aligns with the herb's primary traditional indication, is attributed partly to its mannitol content. However, these findings come from Chinese preclinical study contexts, and no indexed human study has specifically and independently isolated Ming Dang Shen as the active intervention for respiratory outcomes in a clinical trial. Scientific studies evaluating Ming Dang Shen's effects are extremely limited, and most supporting evidence comes from anecdotal reports and historical records rather than controlled clinical trials.
Evidence level: Preclinical; in vitro and animal models only.
Polysaccharides of Changii Radix can promote immune activity and stress resistance, and offer potential application value against cancer and infectious diseases, according to a body of preclinical research summarized in PMC-indexed literature. The mechanistic basis proposed involves polysaccharide-mediated activation of immune effector cells, consistent with the broader pharmacology of plant polysaccharides. No human immunological trial of Changii Radix specifically has been identified in the indexed literature.
Evidence level: In vitro only; highly preliminary.
Research published in Chinese pharmacological journals has examined the in vitro cytotoxicity of five furanocoumarins isolated from the root bark of C. smyrnioides against tumor cell lines. A study specifically examined the antitumor activity of five furanocoumarins from the root bark of Changium smyrnioides in vitro, as referenced in the 2018 review in the Journal of Natural Medicines. No animal models or human trials of Ming Dang Shen for oncological indications have been reported in indexed English-language literature. These findings should be considered entirely preliminary.
Evidence level: Preclinical animal studies; no human trials.
Anti-fatigue and anti-hypoxia effects are among those documented for crude extracts and monomeric compounds isolated from C. smyrnioides in preclinical studies. Antifatigue studies are referenced in the literature as early as 1996, but these are Chinese-language preclinical reports that have not been replicated in prospectively registered human trials accessible through international databases.
Evidence level: Preclinical; no human trials.
The anti-atherosclerotic potential of C. smyrnioides extracts has been noted in published reviews. Antilipemic and anticoagulant activities are among those attributed to Changii Radix in the preclinical literature. The anticoagulant properties, evaluated in studies on clotting time and platelet aggregation, have potential clinical implications but have not been studied in human subjects.
Evidence level: Theoretical/constituent-based; no clinical trial evidence.
Choline, one of the documented active constituents, can prevent the deposition of fat into the liver and can regulate liver and gallbladder functioning. The intestinal motility-promoting effect attributed to polysaccharides provides a plausible mechanistic basis for the traditional use in digestive complaints. The use of Ming Dang Shen for digestive support is documented in classical texts and remains common in herbal practice in East Asia; however, scientific studies evaluating its effects on the digestive system are extremely limited, most evidence comes from anecdotal reports and historical records rather than controlled clinical trials, and there is little direct clinical evidence regarding its efficacy.
Based on the convergence of traditional use records and preclinical pharmacological findings, Ming Dang Shen is primarily associated with the following body systems:
No standardized or internationally recognized dosage has been established for Ming Dang Shen (Changium smyrnioides). The available information regarding dosage forms derives primarily from pharmacopoeial quality specifications and traditional preparation descriptions:
No human clinical trials have reported specific therapeutic dosages for Ming Dang Shen as a monotherapy. The absence of registered clinical trials means there is no verified effective dose, no established dose-response relationship, and no pharmacokinetically determined dosage regimen for this herb in human subjects.
Further studies on the bioactive compounds and mechanisms of C. smyrnioides are necessary, and additional clinical and toxicological studies are warranted to evaluate its safety. This explicit statement from a 2018 systematic review published in the Journal of Natural Medicines (a Springer journal indexed in PubMed) reflects the current state: formal toxicological characterization of the herb remains incomplete.
Research conducted at Nanjing University of Traditional Chinese Medicine has examined the sensitinogen (allergenic substances) profile of the root. A conference-listed study entitled "Study of processing mechanism and allergenic substances of the root of Changium smyrnioides Wolff (Radix Changii)" (Chen J, Li X, Xu H, Cai B, Zhu Q) was presented in the phytochemical conference literature, indicating that allergenic constituents have been formally investigated. The specific sensitinogens identified in that study were not reported in accessible indexed full-text sources, but the investigation's existence signals that allergy risk has been recognized as a research question.
The documented presence of furanocoumarins — including 5-hydroxy-8-methoxypsoralen — in Changium smyrnioides root is a pharmacologically relevant safety consideration. Furanocoumarins, as a structural class, are well-characterized in the broader Apiaceae literature as having phototoxic and, at sufficient concentrations, photosensitizing properties, due to their capacity to intercalate into DNA under UV exposure. The compound 5-hydroxy-8-methoxypsoralen belongs to the psoralen subclass. The clinical significance of furanocoumarin exposure from Changii Radix at typical doses has not been formally assessed in published human pharmacokinetic or safety studies.
No formal herb-drug interaction studies specifically involving Ming Dang Shen and pharmaceutical drugs have been identified in indexed literature. However, several constituent-level theoretical interactions are biochemically plausible and worthy of note based on the known properties of its documented constituents:
Instances of adulteration and substitution using Changium smyrnioides Wolff (Mingdangshen) and other herbs with a similar appearance for other medicinal Apiaceae roots (such as Glehnia littoralis) have been documented. Because multiple Apiaceae roots share similar morphological features, botanical identity verification is important for quality assurance of products labeled as any of these herbs.
Both biological and anthropological factors have contributed to the recent decline of this species, and it is now classified as an endangered species in the Chinese Plant Red Book (Status: Vulnerable species). The conservation status of wild populations adds a supply chain dimension to safety: diminishing wild stocks increase pressure toward cultivation, and separately, toward substitution with adulterants that may have different pharmacological and safety profiles.
The scientific characterization of Ming Dang Shen is substantially less advanced than that of many other widely used Chinese herbal medicines. Key gaps identified in the sourced literature include:
C. smyrnioides is a promising medicinal herb with immense therapeutic and health-promoting effects; therefore, further studies on the bioactive compounds and mechanisms of C. smyrnioides are necessary, and additional clinical and toxicological studies are warranted to evaluate its safety.
Health conditions that Ming dang shen may help support.
Body systems that Ming dang shen may help support.
Go back